Sweden is a constitutional monarchy and a parliamentary democracy. The country joined the European Union in 1995.
The official language is Swedish.
Sweden maintains a Nordic Social Welfare System that provides both universal health care and tertiary education for all the Swedish citizens. Since the healthcare in Sweden is mostly tax-founded, this system ensures that everyone has equal access to healthcare services.
GDP per capita
SEK (1 SEK = 0,09 Euro)
The Swedish health care system is mainly government-funded, universal for all citizens and decentralized, although private health care also exists. The health care system in Sweden is financed primarily through taxes levied by county councils and municipalities. A total of 21 councils are in charge with primary and hospital care within the country.
Private healthcare is rarity in Sweden, and even those private institutions work under the mandated city councils. The city councils regulate the rules and the establishment of potential private practices.
The pharmaceutical industry in Sweden annually spends about 10 billion SEK on research and development in Sweden. Total exports of pharmaceuticals from Sweden in 2015 were approximately 70 billion SEK, and the trade surplus in pharmaceuticals in 2015 was about 32 billion.
Pharmaceuticals are Sweden’s fourth largest export, following road vehicles, machinery and electronics. The value of Swedish pharmaceutical exports in 2018 was nearly twice as large as the value of pharmaceutical imports. Swedish pharma’s principal export markets are Germany, China and the USA, and its pharmaceutical market is the largest in the Nordics region.
People in Sweden are living longer and longer, and the average life span is now 84 years for women and 81 years for men. This ageing population puts pressure on Sweden’s healthcare system.
There’s also a big frustration among the population in Sweden when it comes to the lack of nurses and available doctors in many areas, and the waiting lines are way too long.
Since the Swedish population pays on average more than half their income in tax, they see the access to health care as one of the most important issues.
Henrik Alfredsson & Clas Lindbergson
Challenge us with your case and we will show you the possibilities for your product.
Sales and Marketing
Entering the European market is not easy. 44 countries with different healthcare systems. What is your strategy? Apart from the Big-5, what do you do with the other 28 countries? We offer a solution for 28 countries. Sales and marketing is our core business.Learn more
We manage, through our logistic partners with their regional warehouses, the distribution to our region (28 countries). They have the capability to handle the most demanding of specialized product order management, storage, handling and distribution requirements.Learn more
Early Market Research
You know that market research is critical. It provides customer insights, competitive intelligence, behavioural tendencies, and product positioning. And market research increasingly is becoming an important component for linking R&D and marketing teams.Learn more
Achieving reimbursement and getting the right price are the 2 most important drivers for a successful launch of an innovative pharmaceuticals in our part of Europe. Health Authorities in any European country decide individually based on their local regulations, policies, framework, social values and available health care budget.Learn more
Unlike other regions, in the EU a number of options is available to obtain a marketing authorisation. Centralised at the European Medicines Agency in Amsterdam or decentralised with the individual competent authorities of the member states, each marketing authorisation application procedure has its pros and cons. In the case of Switzerland, it has its own regulatory authority, Swissmedic, and processes.Learn more
Pharmacovigilance is the science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other medicine-related problem.Learn more